enoxacin has been researched along with Bacterial Disease in 49 studies
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.
enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The comparative efficacy of doxycycline versus amoxicillin, cephalexin, cefaclor and enoxacin was examined in four separate cross-over and blinded studies of acute bacterial bronchitis in chronic bronchitis and asthma." | 9.06 | Comparative trials of doxycycline versus amoxicillin, cephalexin and enoxacin in bacterial infections in chronic bronchitis and asthma. ( Chodosh, S; Pizzuto, D; Tuck, J, 1988) |
| "A total of 43 hospitalized adult patients with acute exacerbations of chronic bronchitis or bronchiectasis due to Gram-negative bacteria were randomized to receive either enoxacin (400 mg bd) or amoxycillin (1,000 mg tid) for 7-12 days." | 9.06 | Enoxacin in acute exacerbations of chronic bronchitis: a comparison with amoxycillin. ( Blogie, M; Carpiaux, JP; Glupczynski, Y; Prigogine, T; Schmerber, JS; Yourassowsky, E, 1988) |
| "120 women suffering from acute uncomplicated bacterial cystitis were treated in an open randomized study either with 1 X 400 mg enoxacin or 1 X 3 g amoxicillin per os." | 9.06 | [Comparative studies of enoxacin and amoxicillin for acute uncomplicated cystitis in women]. ( Bischoff, W, 1986) |
| "Enoxacin was administered at the daily dosage of 400 mg every 12 hours for 10 days starting from the enrollment." | 6.66 | [Enoxacin in the treatment of bacterial prostato-cystitis]. ( Austoni, E; Dal Prà, ML; Mandressi, A; Mantovani, F; Mascheroni, E; Montanari, E; Pisani, E, 1989) |
| "Enoxacin was well tolerated." | 5.27 | Efficacy of enoxacin in the treatment of bacterial infections of the skin with regards to photosensitization. ( Petri, H; Tronnier, H, 1986) |
| " In the first trial, long-term residents of Mexico with acute fecal leukocyte-positive diarrhea were randomized to receive trimethoprim/sulfamethoxazole (TMP/SMX), clioquinol or a placebo." | 5.07 | Antimicrobial therapy of bacterial diarrhea in adult residents of Mexico--lack of an effect. ( de la Cabada, FJ; DuPont, HL; Gyr, K; Mathewson, JJ, 1992) |
| "The comparative efficacy of doxycycline versus amoxicillin, cephalexin, cefaclor and enoxacin was examined in four separate cross-over and blinded studies of acute bacterial bronchitis in chronic bronchitis and asthma." | 5.06 | Comparative trials of doxycycline versus amoxicillin, cephalexin and enoxacin in bacterial infections in chronic bronchitis and asthma. ( Chodosh, S; Pizzuto, D; Tuck, J, 1988) |
| "Enoxacin (ENX) was administered to 69 patients with complicated urinary tract infections (UTI)." | 5.06 | [Clinical experience of enoxacin complicated urinary tract infection]. ( Arakawa, M; Kakizaki, H; Kanagawa, K; Koyanagi, T; Maru, A; Minami, S; Nakanishi, S; Sakashita, S; Togashi, M; Tsubo, S, 1988) |
| "A total of 43 hospitalized adult patients with acute exacerbations of chronic bronchitis or bronchiectasis due to Gram-negative bacteria were randomized to receive either enoxacin (400 mg bd) or amoxycillin (1,000 mg tid) for 7-12 days." | 5.06 | Enoxacin in acute exacerbations of chronic bronchitis: a comparison with amoxycillin. ( Blogie, M; Carpiaux, JP; Glupczynski, Y; Prigogine, T; Schmerber, JS; Yourassowsky, E, 1988) |
| "120 women suffering from acute uncomplicated bacterial cystitis were treated in an open randomized study either with 1 X 400 mg enoxacin or 1 X 3 g amoxicillin per os." | 5.06 | [Comparative studies of enoxacin and amoxicillin for acute uncomplicated cystitis in women]. ( Bischoff, W, 1986) |
| "Enoxacin is a new fluoroquinolone compound structurally related to nalidixic acid." | 3.76 | Enoxacin: a new fluoroquinolone. ( Bailey, EM; Jaber, LA; Rybak, MJ, 1989) |
| "Enoxacin, a new orally absorbed broad spectrum anti-microbial agent, was used to treat 25 patients with moderate or severe urinary tract infections." | 3.67 | Enoxacin for the treatment of urinary tract infection. ( Bailey, RR; Peddie, BA, 1985) |
| "In patients with acute nonlymphocytic leukemia, oral enoxacin prevents gram-negative infections, delays the onset of fever, does not alter the incidence of gram-positive or proven deep fungal infections, and is well tolerated." | 2.67 | Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group. ( Bond, L; Cassileth, PA; Correa-Coronas, R; Paradiso, L; Talbot, GH, 1993) |
| "Enoxacin was administered at the daily dosage of 400 mg every 12 hours for 10 days starting from the enrollment." | 2.66 | [Enoxacin in the treatment of bacterial prostato-cystitis]. ( Austoni, E; Dal Prà, ML; Mandressi, A; Mantovani, F; Mascheroni, E; Montanari, E; Pisani, E, 1989) |
| "Enoxacin is a new fluoroquinolone that will be available as oral and intravenous preparations." | 2.38 | Clinical overview of enoxacin. ( Zinner, SH, 1989) |
| " They are well absorbed after oral administration, and some achieve serum and tissue levels well exceeding the minimal inhibitory concentrations for susceptible bacteria." | 2.37 | Symposium on antimicrobial agents. The quinolones. ( Walker, RC; Wright, AJ, 1987) |
| " It is difficult to generalize their clinical usefulness, since these agents exhibit different pharmacokinetic profiles, antimicrobial activity (with varied minimum inhibitory concentrations among similar organisms), and dosage regimens." | 2.37 | Review of the 4-quinolones. ( Eggleston, M; Park, SY, 1987) |
| "Enoxacin treatment was efficacious in 89." | 1.28 | [Treatment of male genital infections with enoxacin]. ( Andreini, F; Bartelloni, M; Campa, M; Canale, D; Di Coscio, M; Giorgi, P; Giorgi, PM; Meschini, P; Poggi, MS; Turchi, P, 1989) |
| "Enoxacin was active against staphylococci (MICs less than or equal to 4 mg/l) but less active against Streptococcus faecalis (MICs mostly 8 mg/l)." | 1.27 | In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates. ( Duncan, IB; Marshall, PW; Skulnick, M, 1984) |
| "Enoxacin was active against virtually all of the species of Enterobacteriaceae tested (MIC90 less than or equal to 0." | 1.27 | Enoxacin: worldwide in-vitro activity against 22451 clinical isolates. ( Siporin, C; Towse, G, 1984) |
| "Enoxacin was also active against Pseudomonas aeruginosa (mean MIC 0." | 1.27 | The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity. ( Bywater, MJ; Holt, HA; Reeves, DS, 1984) |
| "Ciprofloxacin was the most active quinolone tested against both gentamicin-susceptible and gentamicin-resistant stains, having an MIC90 equal or less than 1 mg/l for all species studied." | 1.27 | The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients. ( Guimaraes, MA; Noone, P, 1986) |
| " The pharmacokinetic studies showed high enoxacin concentrations in the secretions, pus, and tissues studied, especially in those of the middle ear and the sinuses." | 1.27 | Clinical and pharmacokinetic studies on enoxacin in ear, nose and throat infections. ( Federspil, PJ; Lind, A; Schmidt, B; Tiesler, E, 1986) |
| "Enoxacin was well tolerated." | 1.27 | Efficacy of enoxacin in the treatment of bacterial infections of the skin with regards to photosensitization. ( Petri, H; Tronnier, H, 1986) |
| "Oral enoxacin was significantly more effective than tobramycin or dicloxacillin in experimental Pseudomonas aeruginosa and Staphylococcus aureus infections respectively." | 1.27 | Enoxacin pharmacokinetics and efficacy in CF-1 mice. ( Chartrand, SA; Dice, J; Marks, MI; Scribner, RK, 1987) |
| "Ofloxacin is a new quinolone carboxylic acid compound." | 1.27 | In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents. ( Kumada, T; Neu, HC, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (89.80) | 18.7374 |
| 1990's | 4 (8.16) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (2.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsumoto, J | 1 |
| Miyamoto, T | 1 |
| Minamida, A | 1 |
| Nishimura, Y | 1 |
| Egawa, H | 1 |
| Nishimura, H | 1 |
| Zhang, J | 1 |
| Ba, Y | 1 |
| Wang, S | 1 |
| Yang, H | 1 |
| Hou, X | 1 |
| Xu, Z | 1 |
| Grassi, C | 1 |
| Mangiarotti, P | 1 |
| Dal Prà, ML | 2 |
| De Cecco, L | 1 |
| Leone, M | 1 |
| Chartrand, SA | 2 |
| Scribner, RK | 2 |
| Weber, AH | 1 |
| Welch, DF | 1 |
| Marks, MI | 2 |
| Nakamura, S | 3 |
| Nakata, K | 2 |
| Katae, H | 2 |
| Minami, A | 3 |
| Kashimoto, S | 2 |
| Yamagishi, J | 2 |
| Takase, Y | 2 |
| Shimizu, M | 2 |
| Kouno, K | 2 |
| Inoue, M | 1 |
| Mitsuhashi, S | 1 |
| Bauernfeind, A | 1 |
| Ullmann, U | 1 |
| Duncan, IB | 1 |
| Skulnick, M | 1 |
| Marshall, PW | 1 |
| Miki, F | 1 |
| Saito, A | 1 |
| Tomizawa, M | 1 |
| Nakayama, I | 1 |
| Takebe, K | 1 |
| Takashima, T | 1 |
| Ida, S | 1 |
| Konno, K | 1 |
| Oizumi, K | 1 |
| Sasaki, M | 1 |
| Hashimoto, H | 1 |
| Sagara, H | 1 |
| Matsubara, Y | 1 |
| Tomizawa, I | 1 |
| Takizawa, Y | 1 |
| Ito, K | 1 |
| Konishi, K | 1 |
| Matsunaga, M | 1 |
| Yanagishita, T | 1 |
| Kosugi, M | 1 |
| Inoue, S | 1 |
| Grimm, H | 1 |
| Siporin, C | 1 |
| Towse, G | 1 |
| Reeves, DS | 1 |
| Bywater, MJ | 1 |
| Holt, HA | 1 |
| Talbot, GH | 1 |
| Cassileth, PA | 1 |
| Paradiso, L | 1 |
| Correa-Coronas, R | 1 |
| Bond, L | 1 |
| Koga, H | 1 |
| Aoyagi, K | 1 |
| Yoshimura, R | 1 |
| Kimura, Y | 1 |
| Iida, M | 1 |
| Fujishima, M | 1 |
| de la Cabada, FJ | 1 |
| DuPont, HL | 1 |
| Gyr, K | 1 |
| Mathewson, JJ | 1 |
| Lombardo, F | 1 |
| Gandini, L | 1 |
| Alfano, P | 1 |
| Anticoli Borza, L | 1 |
| Lenzi, A | 1 |
| Dondero, F | 1 |
| Tocci, G | 1 |
| Visco, G | 1 |
| Marchioni, CF | 1 |
| Bernini, S | 1 |
| Lunghi, P | 1 |
| Guerzoni, P | 1 |
| Giorgi, PM | 1 |
| Giorgi, P | 1 |
| Canale, D | 1 |
| Turchi, P | 1 |
| Poggi, MS | 1 |
| Di Coscio, M | 1 |
| Bartelloni, M | 1 |
| Meschini, P | 1 |
| Andreini, F | 1 |
| Campa, M | 1 |
| Mantovani, F | 1 |
| Mascheroni, E | 1 |
| Montanari, E | 1 |
| Mandressi, A | 1 |
| Austoni, E | 1 |
| Pisani, E | 1 |
| Jaber, LA | 1 |
| Bailey, EM | 1 |
| Rybak, MJ | 1 |
| Fong, IW | 1 |
| Naumann, P | 1 |
| Dopp, C | 1 |
| Zinner, SH | 1 |
| Kurobe, N | 1 |
| Sakaguchi, Y | 1 |
| Yoshida, H | 1 |
| Kojima, T | 1 |
| Ohue, T | 1 |
| Guimaraes, MA | 1 |
| Noone, P | 1 |
| Davies, BI | 2 |
| Maesen, FP | 2 |
| Teengs, JP | 2 |
| Baur, C | 2 |
| Høiby, N | 1 |
| Chodosh, S | 1 |
| Tuck, J | 1 |
| Pizzuto, D | 1 |
| Togashi, M | 1 |
| Arakawa, M | 1 |
| Tsubo, S | 1 |
| Sakashita, S | 1 |
| Maru, A | 1 |
| Koyanagi, T | 1 |
| Nakanishi, S | 1 |
| Kakizaki, H | 1 |
| Minami, S | 1 |
| Kanagawa, K | 1 |
| Prigogine, T | 1 |
| Glupczynski, Y | 1 |
| Carpiaux, JP | 1 |
| Blogie, M | 1 |
| Yourassowsky, E | 1 |
| Schmerber, JS | 1 |
| Tanimura, H | 1 |
| Aoki, Y | 1 |
| Uesaka, K | 1 |
| Kasano, Y | 1 |
| Nakai, T | 1 |
| Kitamura, T | 1 |
| Mukaihara, S | 1 |
| Tamura, K | 1 |
| Yotsumoto, F | 1 |
| Terao, R | 1 |
| Roe, CJ | 1 |
| Becker, GJ | 1 |
| Whitworth, JA | 1 |
| Kincaid-Smith, P | 1 |
| Walker, RC | 1 |
| Wright, AJ | 1 |
| Shah, PM | 1 |
| Bischoff, W | 1 |
| Federspil, PJ | 1 |
| Lind, A | 1 |
| Tiesler, E | 1 |
| Schmidt, B | 1 |
| Petri, H | 1 |
| Tronnier, H | 1 |
| Rolston, KV | 1 |
| Ho, DH | 1 |
| LeBlanc, B | 1 |
| Bodey, GP | 1 |
| Mensing, H | 1 |
| Neu, HC | 2 |
| Eggleston, M | 1 |
| Park, SY | 1 |
| Dice, J | 1 |
| Bailey, RR | 1 |
| Peddie, BA | 1 |
| Kumada, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Irinotecan Induced Diarrhea by Probiotics: A Phase III Study[NCT02819960] | Phase 3 | 233 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for enoxacin and Bacterial Disease
| Article | Year |
|---|---|
Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
Topics: Anti-Bacterial Agents; Bacterial Infections; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; | 2019 |
Enoxacin: a new fluoroquinolone.
Topics: Animals; Bacterial Infections; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Drug Interac | 1989 |
Clinical overview of enoxacin.
Topics: Bacterial Infections; Enoxacin; Humans | 1989 |
Symposium on antimicrobial agents. The quinolones.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1987 |
Quinolones.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Enoxacin | 1987 |
New antibiotics: areas of appropriate use.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Infections; beta-Lactamase Inhibitors; Cephalosporins; C | 1987 |
Review of the 4-quinolones.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Interactions; Drug Resist | 1987 |
13 trials available for enoxacin and Bacterial Disease
| Article | Year |
|---|---|
[Comparative study of the effectiveness of enoxacin and amoxicillin in bacterial pneumonia by a double blind method].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Clinical Trials as | 1984 |
[Comparison of clinical usefulness of enoxacin (ENX, AT-2266) and pipemidic acid (PPA) in the treatment of acute infectious diarrhea by a double-blind method. The Japan Research Committee of Enoxacin Research Group for Acute Infectious Diarrhea].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Clinical Trials as T | 1984 |
Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Double-Blind Method; Enoxacin; Female; Huma | 1993 |
Antimicrobial therapy of bacterial diarrhea in adult residents of Mexico--lack of an effect.
Topics: Adult; Bacterial Infections; Clioquinol; Diarrhea; Double-Blind Method; Enoxacin; Female; Humans; Ma | 1992 |
[Enoxacin in the treatment of bacterial prostato-cystitis].
Topics: Acute Disease; Adult; Aged; Bacterial Infections; Chronic Disease; Clinical Trials as Topic; Cystiti | 1989 |
Enoxacin: a new fluoroquinolone.
Topics: Animals; Bacterial Infections; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Drug Interac | 1989 |
The role of fluoroquinolones in the management of skin, soft tissue, and bone infections.
Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Dermatitis; En | 1989 |
Comparative trials of doxycycline versus amoxicillin, cephalexin and enoxacin in bacterial infections in chronic bronchitis and asthma.
Topics: Adult; Amoxicillin; Asthma; Bacterial Infections; Bronchitis; Cephalexin; Clinical Trials as Topic; | 1988 |
[Clinical experience of enoxacin complicated urinary tract infection].
Topics: Adult; Aged; Aged, 80 and over; Bacteria; Bacterial Infections; Chemical Phenomena; Chemistry; Drug | 1988 |
Enoxacin in acute exacerbations of chronic bronchitis: a comparison with amoxycillin.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bacterial Infecti | 1988 |
Enoxacin in the treatment of complicated urinary tract infections.
Topics: Adult; Aged; Bacterial Infections; Clinical Trials as Topic; Enoxacin; Female; Humans; Middle Aged; | 1987 |
[Comparative studies of enoxacin and amoxicillin for acute uncomplicated cystitis in women].
Topics: Acute Disease; Amoxicillin; Anti-Infective Agents; Bacterial Infections; Cystitis; Enoxacin; Female; | 1986 |
[Results of treatment of bacterial inflammation of the skin with enoxacin].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Clinical Tr | 1986 |
30 other studies available for enoxacin and Bacterial Disease
| Article | Year |
|---|---|
Pyridonecarboxylic acids as antibacterial agents. 2. Synthesis and structure-activity relationships of 1,6,7-trisubstituted 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids, including enoxacin, a new antibacterial agent.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Enoxacin; Escherichia coli; Mice; Naphthyridin | 1984 |
Enoxacin: clinical results in lower respiratory tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria; Bacterial Infections; C | 1989 |
Enoxacin in urinary tract infections associated with gynecological diseases.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Enoxacin; Female; Ge | 1989 |
In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Stability; Enoxacin; Humans; Microbial S | 1983 |
Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Enoxacin; Gentamicins; Male; Mice; Nalidixic A | 1983 |
In vitro and in vivo antibacterial activity of AT-2266.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Enoxacin | 1983 |
In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
Topics: Bacteria; Bacterial Infections; Enoxacin; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Napht | 1984 |
In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Drug Resistance, Microbial; Enoxacin; | 1984 |
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cholic Acid; Cholic Acids; Drug Resistance, M | 1983 |
Interpretive criteria for the agar diffusion susceptibility test with enoxacin.
Topics: Agar; Bacteria; Bacterial Infections; Diffusion; Enoxacin; Microbial Sensitivity Tests; Naphthyridin | 1984 |
Enoxacin: worldwide in-vitro activity against 22451 clinical isolates.
Topics: Bacteria; Bacterial Infections; Enoxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Mi | 1984 |
The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity.
Topics: Bacteria; Bacterial Infections; Culture Media; Drug Resistance, Microbial; Enoxacin; Humans; Hydroge | 1984 |
Can quinolones cause hemorrhagic colitis of late onset? Report of three cases.
Topics: Acute Disease; Adult; Anti-Infective Agents; Bacterial Infections; Colitis; Colonoscopy; Enoxacin; F | 1999 |
[Enoxacin in the treatment of male genital infections in patients with antisperm autoimmune pathology].
Topics: Adult; Autoimmune Diseases; Bacterial Infections; Enoxacin; Genital Diseases, Male; Humans; Male; Sp | 1990 |
[Enoxacin in the treatment of bacterial infections of the urinary tract].
Topics: Adult; Aged; Bacterial Infections; Drug Evaluation; Enoxacin; Female; Humans; Male; Middle Aged; Uri | 1989 |
[Enoxacin in the treatment of bacterial infections of the respiratory system].
Topics: Adult; Aged; Bacterial Infections; Bronchitis; Drug Evaluation; Enoxacin; Female; Humans; Male; Midd | 1989 |
[Treatment of male genital infections with enoxacin].
Topics: Adult; Bacterial Infections; Cystitis; Enoxacin; Humans; Infertility, Male; Male; Middle Aged; Prost | 1989 |
[Fluoroquinolones--antibacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs].
Topics: Adult; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Dose-Response Relations | 1989 |
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquino | 1989 |
The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
Topics: Acinetobacter; Bacteria; Bacterial Infections; Ciprofloxacin; Citrobacter; Drug Resistance, Microbia | 1986 |
[New oral quinolone compounds in chronic bronchitis].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Cipr | 1986 |
Clinical uses of nalidixic acid analogues: the fluoroquinolones.
Topics: Administration, Oral; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Evaluation; D | 1986 |
[Chemotherapy for biliary tract infection (XXXIII). Tissue concentration of NY-198 in gallbladder, biliary excretion and clinical effects].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Bile; Cholangitis; Chol | 1988 |
Clinical and pharmacokinetic studies on enoxacin in ear, nose and throat infections.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Enoxacin; Female; Humans; Kinetics; Male; Naphth | 1986 |
Efficacy of enoxacin in the treatment of bacterial infections of the skin with regards to photosensitization.
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Enoxacin; Female; Humans; Male; Middle Age | 1986 |
Quinolone antimicrobial agents in acute exacerbations of chronic bronchitis.
Topics: Anti-Infective Agents; Bacterial Infections; Bronchitis; Ciprofloxacin; Enoxacin; Female; Humans; Ma | 1986 |
In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquinolones; Gram-Negativ | 1987 |
Enoxacin pharmacokinetics and efficacy in CF-1 mice.
Topics: Analysis of Variance; Animals; Anti-Infective Agents; Bacterial Infections; Disease Models, Animal; | 1987 |
Enoxacin for the treatment of urinary tract infection.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents, Urinary; Bacterial Infections; Enoxacin; Female; Hum | 1985 |
In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Enoxacin | 1985 |